Edit
Sagent Pharmaceuticals
http://www.sagentpharma.com/?portfolioCats=34,23,29,35,22,24,30,25,28,31#new_tabLast activity: 10.05.2024
Sagent Holding Co. is a generic specialty injectable (“SIP”) pharmaceutical company targeting the US hospital and clinical markets, with manufacturing facilities in China and sales, marketing and distribution in the US. Founded in late 2006, Sagent leverages global R&D resources, US distribution and Chinese manufacturing to realize increased value along the supply chain and higher return on equity.
CRCI successfully exited this investment in November 2011, at 2.0x ROI and 25.5% IRR.
赛金药业是一家专门针对美国医院和临床市场的非专利特效注射剂（“ SIP”）制药公司，在中国设有制造工厂，销售、市场及分支机构在美国。 赛金药业成立于2006年底，该公司充分利用全球研发资源、美国分销与中国制造，来实现供应链增值和更高的股权投资回报。
崇德投资于2011年11月以2.0倍的投资回报率和25.5％的内部收益率成功退出了此项投资。
Total raised: $30M
Investors 2
| Date | Name | Website |
| 10.05.2024 | China Rena... | crcicapita... |
| - | Vivo Capit... | vivocapita... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 21.05.2009 | Series A | $30M | - |
Mentions in press and media 5
| Date | Title | Description |
| 12.02.2021 | Sagent Pharmaceuticals Announces Start of NIAID-Sponsored Study Investigating COVID-19 Treatments in Outpatients | |
| 08.04.2010 | Sagent Pharmaceuticals Raises $40M | Sagent Pharmaceuticals, a Schaumburg, IL-based pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical injectable products, has raised $40m through two tranches of a strategic Series B financing. I... |
| 21.05.2009 | Sagent Pharmaceuticals raises $30 million; total Series A round to $113 million | Promoted Clinical Care Capacity Planning Learn how to manage clinical care capacity more efficiently during uncertain times. SAP Promoted Telemedicine’s potential to provide healthcare to the world’s most vulnerable Teladoc Health Head of R... |
| 28.09.2007 | Life sciences briefing: Friday, Sept. 28, 2007 | Featured companies: Imalux, Sagent Pharmaceuticals, Sequel Pharmaceuticals, Sinexus, TranS1, U.S. Spinal Technologies Sagent Pharmaceuticals draws in $53M for injectable generics — Sagent Pharmaceuticals, proving that there’s still life in ... |
| - | Sagent Pharmaceuticals raises $30 million; total Series A round to $113 million | SCHAUMBURG, Illinois — Injectable drug manufacturer Sagent Pharmaceuticals closed its second $30 million Series A extension this week to help launch new products and other activities, the company stated. Sagent originally raised $53 million... |